Tatva Chintan Pharma Chem Ltd Q2FY22 consolidated PAT surges to Rs. 32.41 crore

The Board of Directors of , at its meeting held today have approved the unaudited Consolidated financial results of the company for the period ended September 30, 2021.

For the quarter ended September 30, 2021(Q2 FY2022), the company's total income was ₹ 126.419 crore, against ₹61.991 crore in the corresponding quarter of the previous year (YoY) and ₹108.597 crore in previous quarter (QoQ).

For the quarter ended September 30, 2021(Q2 FY2022), the company's net profit / (loss) was ₹32.412 crore, against ₹3.556 crore in the corresponding quarter of the previous year (YoY) and ₹23.146 crore in previous quarter (QoQ).

For the quarter ended September 30, 2021(Q2 FY2022), the company's Earnings Per Share (EPS) was ₹15.02, against ₹1.77 in the corresponding quarter of the previous year (YoY) and ₹11.52 in previous quarter (QoQ).

Financials	Q2 FY2022	Q1 FY2022	QoQ % Change	Q2 FY2021	YoY % Change
Total Income	₹ 126.419 crs	₹108.597 crs	16.41%	₹61.991 crs	103.93%
Net Profit	₹32.412 crs	₹23.146 crs	40.03%	₹3.556 crs	811.47 %
EPS	₹15.02	₹11.52	30.38%	₹1.77	748.59%

For the 6 Months period ended September 30, 2021(Half Year Ended FY 2022), the company's total income was ₹235.016 crore, against ₹114.262 crore in the previous year (YoY) (Half Year Ended FY 2021).

The net profit / (loss) was at ₹55.558 crore for the 6 Months period ended September 30, 2021 (Half Year Ended FY 2022), compared to ₹10.266 crore in the previous year (YoY) (Half Year Ended FY 2021).

The Earnings Per Share stood at ₹26.66 for the 6 Months period ended September 30, 2021 (Half Year Ended FY 2022), against ₹5.11 in the previous year (YoY) (Half Year Ended FY 2021).

Financials	Half Year Ended FY2022	Half Year Ended FY2021	% Change
Total Income	₹235.016 crs	₹114.262 crs	105.68%
Net Profit	₹55.558 crs	₹10.266 crs	441.18%
EPS	₹26.66	₹5.11	421.72%

Source : Equity Bulls

Keywords

TatvaChintanPharmaChem Q2FY22 H1FY22 ResultUpdate